Literature DB >> 31139959

In vivo direct relation of tau pathology with neuroinflammation in early Alzheimer's disease.

Tatsuhiro Terada1,2, Masamichi Yokokura3, Tomokazu Obi2, Tomoyasu Bunai1, Etsuji Yoshikawa4, Ichiro Ando5, Hitoshi Shimada6, Tetsuya Suhara6, Makoto Higuchi6, Yasuomi Ouchi7.   

Abstract

OBJECTIVE: Neuronal damage and neuroinflammation are important events occurring in the brain of Alzheimer's disease (AD). The purpose of this study was to clarify in vivo mutual relationships among abnormal tau deposition, neuroinflammation and cognitive impairment in patients with early AD using positron emission tomography (PET) with [11C]PBB3 and [11C]DPA713.
METHODS: Twenty patients with early AD and 20 age-matched normal control (NC) subjects underwent a series of PET measurements with [11C]PBB3 for tau aggregation and [11C]DPA713 for microglial activation (neuroinflammation). Inter- and intrasubject comparisons were performed regarding the levels of [11C]PBB3 binding potential (BPND) and [11C]DPA713 BPND in the light of cognitive functions using statistical parametric mapping (SPM) and regions of interest (ROIs) method.
RESULTS: The [11C]PBB3 BPND was greater in the temporo-parietal regions of AD patents than NC subjects, and a similar increasing pattern of [11C]DPA713 BPND was observed in the same patients. Correlation analyses within the AD group showed a positive direct correlation between [11C]PBB3 BPND and [11C]DPA713 BPND in the parahippocampus. Pass analysis revealed that cognitive impairment was more likely linked to the level of the parahippocampal [11C]PBB3 BPND than that of [11C]DPA713 BPND.
CONCLUSIONS: The pattern of abnormal tau deposition was very similar to that of neuroinflammation in patients with early-stage AD. Specifically, the direct positive correlation of tau pathology with neuroinflammation in the parahippocampus suggests that neuronal damage in this region is closely associated with microglial activation. Consistently, tau aggregation in this region matters more than neuroinflammation regarding the cognitive deterioration in AD.

Entities:  

Keywords:  Alzheimer’s disease; Microglia; Positron emission tomography; TAU; [11C]PBB3

Mesh:

Substances:

Year:  2019        PMID: 31139959     DOI: 10.1007/s00415-019-09400-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  22 in total

Review 1.  The Brain's Glymphatic System: Current Controversies.

Authors:  Humberto Mestre; Yuki Mori; Maiken Nedergaard
Journal:  Trends Neurosci       Date:  2020-05-15       Impact factor: 13.837

2.  Microtube Array Membrane Encapsulated Cell Therapy: A Novel Platform Technology Solution for Treatment of Alzheimer's Disease.

Authors:  Shu-Mei Chen; Tsung-Chin Hsu; Chee-Ho Chew; Wan-Ting Huang; Amanda Lin Chen; Yung-Feng Lin; Sabiha Eddarkaoui; Luc Buee; Chien-Chung Chen
Journal:  Int J Mol Sci       Date:  2022-06-20       Impact factor: 6.208

Review 3.  Microglia Biomarkers in Alzheimer's Disease.

Authors:  Peng-Fei Zhang; Hao Hu; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2021-03-12       Impact factor: 5.590

4.  Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer's disease.

Authors:  Tatsuhiro Terada; Joseph Therriault; Min Su Peter Kang; Melissa Savard; Tharick Ali Pascoal; Firoza Lussier; Cecile Tissot; Yi-Ting Wang; Andrea Benedet; Takashi Matsudaira; Tomoyasu Bunai; Tomokazu Obi; Hideo Tsukada; Yasuomi Ouchi; Pedro Rosa-Neto
Journal:  Mol Neurodegener       Date:  2021-04-26       Impact factor: 14.195

Review 5.  PET imaging of neuroinflammation in neurological disorders.

Authors:  William C Kreisl; Min-Jeong Kim; Jennifer M Coughlin; Ioline D Henter; David R Owen; Robert B Innis
Journal:  Lancet Neurol       Date:  2020-11       Impact factor: 44.182

Review 6.  Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.

Authors:  Konstantinos Chiotis; Alessandra Dodich; Marina Boccardi; Cristina Festari; Alexander Drzezga; Oskar Hansson; Rik Ossenkoppele; Giovanni Frisoni; Valentina Garibotto; Agneta Nordberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-15       Impact factor: 9.236

7.  Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.

Authors:  Maura Malpetti; Rogier A Kievit; Luca Passamonti; P Simon Jones; Kamen A Tsvetanov; Timothy Rittman; Elijah Mak; Nicolas Nicastro; W Richard Bevan-Jones; Li Su; Young T Hong; Tim D Fryer; Franklin I Aigbirhio; John T O'Brien; James B Rowe
Journal:  Brain       Date:  2020-05-01       Impact factor: 13.501

Review 8.  Glymphatic failure as a final common pathway to dementia.

Authors:  Maiken Nedergaard; Steven A Goldman
Journal:  Science       Date:  2020-10-02       Impact factor: 47.728

Review 9.  Neurological Mechanisms of Animal-Assisted Intervention in Alzheimer's Disease: A Hypothetical Review.

Authors:  Sujin Kim; Yunkwon Nam; Min-Joo Ham; Chisoo Park; Minho Moon; Doo-Han Yoo
Journal:  Front Aging Neurosci       Date:  2021-07-14       Impact factor: 5.750

Review 10.  Oligomerization and Conformational Change Turn Monomeric β-Amyloid and Tau Proteins Toxic: Their Role in Alzheimer's Pathogenesis.

Authors:  Botond Penke; Mária Szűcs; Ferenc Bogár
Journal:  Molecules       Date:  2020-04-03       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.